WellbeingPROMOTENCT06566157
PROMOTE: The Effect of a Six Week Prebiotic Supplementation on Wellbeing of Young Adults.
A study testing Prebiotic and Maltodextrin (Corn) in people with Wellbeing and Healthy, run by University of Southampton at 1 site in United Kingdom.
Trial summary
The study will investigate whether taking a prebiotic for six weeks helps to reduce morning cortisol levels in healthy young adults with mild to moderate stress compared to a placebo. Individuals should continue with their usual lifestyle during the study. Other factors of wellbeing will also be assessed. Read more about this study
- Who is it for?
- Ages 18 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Wellbeing, Healthy, Mental Health
- What is being tested?
- Prebiotic and Maltodextrin (Corn)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 6 Jan 2025to 16 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Aged 18-25 at time of recruitment
- Body Mass Index (18.5 - 29.9 kg) : Healthy - Overweight
- Stress score of 15≤ - ≥25 (DASS)
- Willing and with capacity to give informed consent to participate at time of recruitment
- Speak and comprehend English to a good standard
- In good general health
- Willing to provide stool, urine and blood (8mL) sample during intervention
- Willing to attend 4 visits to Southampton General Hospital Clinical Research Facility over 10-11 weeks
Who cannot join
- Consuming ≥ 14 units of alcohol/week (6 x 175 mL of wine, 6 pints of 4% beer)
- Learning or behavioural difficulties (assessed on individual basis)
- Planning a pregnancy in the next 6 months, pregnant, lactating or had a recent birth ≥6 months
- Currently smoking or using e-cigarette, vape
- Vulnerable adults (with self reported sever or very severe stress score (DASS)
- Unwilling to suspend existing probiotic / prebiotic supplementation (with additional 4 weeks washout) before starting study.
Show all 14Show fewer
- Medical exclusions:
- Actively involved in therapy or psychiatric intervention of a diagnosed mental health condition
- Prescribed psychotropic medication (Antidepressants, Monoamine Oxidase Inhibitors (MAOI's), Antipsychotics, sleeping pills, mood stabilisers etc)
- Allergic to milk, soy, corn, penicillin or fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPS)
- Currently prescribed laxatives, enemas, anti-coagulants or painkillers
- Existing medical condition: cancer, hepatobiliary surgery, diabetes or diagnosed gastrointestinal diseases (irritable bowel disease, ulcerative colitis)
- Involved in a recent pharmacology/psychological intervention, last 6 months
- Recent antibiotic prescription, last 6 months
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
NIHR Southampton Clinical Research Facility
Southampton, Hampshire, SO16 6YD
About this study
Official title: PROMOTE: The Effect of Prebiotic Supplementation on Salivary Cortisol Awakening Response in Young Adults With Mild-To-Moderate Self-Reported Stress: A Double Blinded Parallel Randomised Controlled-Trial.
The study will investigate whether taking a prebiotic for six weeks helps to reduce morning cortisol levels in healthy young adults with mild to moderate stress compared to a placebo. Individuals should continue with their usual lifestyle during the study. Other factors of wellbeing will also be assessed.
Read the detailed description
PROMOTE is a double blinded parallel randomised controlled-trial investigating if prebiotic supplementation reduce awakening salivary cortisol response, reported as area under the curve compared to a maltodextrin placebo in healthy young adults with a mild-to-moderate self reported stress score. There will be a focus on biological secondary outcomes to better understand how supplementation may influence the microbiome using metabolomics and sequencing techniques. In addition to other measures of wellbeing captured by questionnaires and activity monitors.
- Conditions
- Wellbeing, Healthy, Mental Health
- Being tested
- Prebiotic, Maltodextrin (Corn)
- Keywords
- Prebiotics, Gut microbiome, Microbiome, Metabolomics, Sequencing, Stress, Wellbeing
- Medical subject headings
- Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PrebioticDietary supplement
Also called WellBiome®, WellBiome® - Mineral Enriched Prebiotic Fibre Complex, Inulin, XOS
WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %
Maltodextrin (Corn)Dietary supplement
Also called Maltodextrin Placebo
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Prebiotic | Experimental | WellBiome® prebiotic complex Inulin 67%, Xylooligosaccharides (XOS) 27%, Magnesium Chloride (MgCl2) 9.8 % Receives: Dietary Supplement: Prebiotic |
| Maltodextrin | Placebo comparator | Maltodextrin (Corn origin) Receives: Dietary Supplement: Maltodextrin (Corn) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Salivary Cortisol Awakening Response - Biological salivary cortisol (µg/dL)
Salivary Cortisol Awakening Response (µg/dL) Measured on awakening and hereafter at 0, 15 , 30, 45 minutes Quantified by ELISA and presented as area under the curve, for each timepoint.
Example outcome: 'Awakening salivary cortisol response was significantly lower in the prebiotic group compared to the placebo mean difference: -2.27( 95CI-3.68, -0.87) group after 6 weeks of supplementation.' [result sourced from clinicaltrials.gov NCT0521254]
Measured: 6 collections across two working mornings per timepoint. (2 'baseline' - week 0 before supplementation; 2 'endpoint' - week 6 of supplementation ; 2 'follow-up' - within 3rd week (week 9) of supplement end)
Secondary outcomes (10)
Good Sleeper Scale -15 items (GSS -15) self-reported sleep.
GSS-15 - Manners, J et al (2023) questionnaire A 15 item questionnaire validated in a population of Australian adults to give a self-reported indices of sleep on a scale of confidence of being a good sleeper.
10.1111/jsr.13717
GSS-15 ≥ 45: High confidence of being a Good Sleeper GSS-15 40 - 44: Moderate confidence of being a Good Sleeper GSS-15 < 40: Low confidence of being a Good Sleeper
Example outcome: 'There was no difference in the mean reported good sleeper score (43.25 43.25 (95% CI: -40.1, 46.2) of the prebiotic and placebo groups after 6 weeks of supplementation.'
Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Depression Anxiety and Stress Scales 42-items (DASS-42) questionnaire. Wellbeing and subjective mental health assessment.
Depression, Anxiety and Stress Scales Lovibond, P. F., \& Lovibond, S. H. (1995) 10.1016/0005-7967(94)00075-u
Scale Scores:
DASS (42) Scores are calculated for each subset of the survey with the scale as follows where lower scores indicate a better outcome, while higher scores indicate worse results:
Depression Anxiety Stress Normal 0-9 0-7 0-14 Mild 10-13 8-9 15-18 Moderate 14-20 10-14 19-25 Severe 21-27 15-19 26-33 Extremely Severe 28+ 20+ 34+
Example outcome: 'There was a significant reduction in the stress score observed in the prebiotic group (mean: -3.25 (p=0.004) after 6 weeks of supplementation when compared to the placebo group.'
Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Faceal microbial sequencing and interventional group microbiota compositional change
16S ribosomal ribonucleic acid (rRNA) sequencing of stool samples measuring microbial composition change.
Units: Read counts, Operational Taxanomic Units (OTUs) and Relative abundance provide quantifications of the amount of bacterial genetic sequence present in a stool sample building an approximation of the faecal microbial composition to at least the genus level.
Results are typical reported in compositional scores like alpha and beta diversity.
Bray-Curtis dissimilarity is a scale of similarity where values closer to 1 are more distinct, while values close to 0 represent similar compositions.
Example outcome: 'The beta diversity (a measure of compositional change) of the prebiotic group using Bray-Curtis dissimilarity increased by 22.7%, suggesting a compositional change from the placebo group.'
Measured: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).
Short Food Frequency Questionnaire (SFFQ): Diet quality score
Validated SFFQ for adults in the United Kingdom (UK) Cleghorn, CL. et al (2017) - University of Leeds
Scores per subgroup (Fruit, Vegetables, Oily Fish, Fat and Non-Milk Extrinsic Sugars (NMEs)) are converted to scores ranging from 1-3 based on consumption. Lower scores indicating less intake, while scores of 3 indicate high intake of particular food groups (except for fats and NMEs which is reverse scaled - lower score matching closer to nutritional guideline).
A final dietary quality score score is calculated from all subgroups with higher scores indicating better dietary quality.
Example outcome: 'Dietary quality scores did not significantly differ among the prebiotic and placebo groups after 6 weeks. This indicates that participants' dietary habits remained consistent throughout the intervention, thereby minimizing dietary intake as a confounding factor in the comparison of the interventional groups.'
Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Activity monitoring using activewear devices
Subsample analysis of biometric activity and sleep using FitBit Inspire 3.0. The Fitbit Inspire 2.0 can capture more objective measures of sleep including time spent in REM sleep phases, sleep duration, awakening and sleep latency.
Example outcome: 'Sleep latency, defined as the time taken to fall asleep, was significantly reduced by 5.5 minutes (p < 0.05) after 6 weeks of prebiotic supplementation compared to the placebo group.'
Measured: Continuous / 3 nights per 14 days (2 weeknights, 1 weekend night) depending on participants preference.
Urine Metabolomics (Untargeted)
Untargeted Proton Nuclear Magnetic Resonance (1H NMR) metabolomic analysis of urine samples.
NMR generates a spectrum of metabolites by detecting hydrogen atoms' response to an electromagnetic pulse. The resulting peaks correspond to specific chemical shift ranges (δ shifts), allowing for the identification of metabolite compositions. It is untargeted as identification is based on what is returned in spectral form, as opposed to targeted which preselects specific metabolites to measure.
Example outcome: 'After 6 weeks of prebiotic supplementation, we observed significant increases in the urinary levels of dimethylglycine, indole-3-sulfate, and hippurate compared to the placebo group. These findings suggest that prebiotic supplementation may influence various metabolic pathways and gut microbiota activity.'
Measured: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).
Faeces Metabolomics (Untargeted)
Untargeted Proton Nuclear Magnetic Resonance (1H NMR) metabolomic analysis of faeces.
NMR generates a spectrum of metabolites by detecting hydrogen atoms' response to an electromagnetic pulse. The resulting peaks correspond to specific chemical shift ranges (δ shifts), allowing for the identification of metabolite compositions. It is untargeted as identification is based on what is returned in spectral form, as opposed to targeted which preselects specific metabolites to measure.
Example outcome: 'After 6 weeks of prebiotic supplementation, we observed significant increases in the faecal levels of alanine and glutamate compared to the placebo group.
More targeted approaches would be needed to quantify and determine if these amino acids are from dietary, human or microbiome origins like Liquid Chromatography Mass Spectrometry LC-MS).'
Measured: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).
Plasma Metabolomics (Untargeted)
Untargeted Proton Nuclear Magnetic Resonance (1H NMR) metabolomic analysis of plasma samples.
NMR generates a spectrum of metabolites by detecting hydrogen atoms' response to an electromagnetic pulse. The resulting peaks correspond to specific chemical shift ranges (δ shifts), allowing for the identification of metabolite compositions. It is untargeted as identification is based on what is returned in spectral form, as opposed to targeted which preselects specific metabolites to measure.
Example outcome: 'After 6 weeks, prebiotic supplementation significantly increased faecal levels of alanine and glutamate compared to placebo, while lysine levels remained unchanged. Further targeted analyses, such as LC-MS, are needed to determine the origins and concentrations of these amino acids'.
Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Anthropometrics - Body composition
Height (cm), Weight (Kg), Waist Circumference (cm) and Body Mass Index (BMI (kg/m2)
Example outcome: 'Mean waist circumference (cm) did not differ significantly (p > 0.05) between the prebiotic and placebo groups after 6 weeks, suggesting that the prebiotic had no effect on body composition in terms of waist circumference.'
Measured: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Adverse effects monitoring
Monitoring or reporting of any adverse or severe adverse effects experienced during intervention.
Reported and logged in active survey responses / contacting the study team directly
Example outcome: 'There were two minor side effects reported early in the prebiotic supplementation, both instances self resolved within a few days and may be an effect of the initial introduction of a supplement to the individuals digestive system. No severe adverse effects were reported in either the prebiotic or the placebo control groups.'
Measured: Continuous monitoring from start to end of study for all participants
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2024
- Study start6 Jan 2025 (estimated)
- Primary completion16 Sep 2025 (estimated)
- Study completion16 Sep 2026 (estimated)
Why it stopped: Funding partners dissolved prior to study launch
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for WellbeingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double blind, Placebo, Randomised
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Southampton
- Sponsor type
- University, hospital or other
- Collaborators
- OptiBiotix Health Plc
- Responsible party
- Sponsor
- Investigators
- Jonathan R Swann, Professor, Principal investigator, University of Southampton, Faculty of Medicine - Human Development and Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06566157
- Sponsor's protocol ID
- 340693
- Other IDs
- 89554
- Acronym
- PROMOTE
- Status last verified
- Dec 2024
- First submitted
- 7 Aug 2024
- Last updated
- 13 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will be anonymised and submitted to open access repositories upon the consent and permission of the participants. Biological data will not be available for secondary analysis but raw exports of biological data in anonymous form can be made available on conditional request provided ethics approval from a suitable institution is met.
Publications
Caspani G, Swann J. Small talk: microbial metabolites involved in the signaling from microbiota to brain. Curr Opin Pharmacol. 2019 Oct;48:99-106. doi: 10.1016/j.coph.2019.08.001. Epub 2019 Sep 14.
PubMed 31525562
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PROMOTE: The Effect of Prebiotic Supplementation on Salivary Cortisol Awakening Response in Young Adults With Mild-To-Moderate Self-Reported Stress: A Double Blinded Parallel Randomised Controlled-Trial.
- ClinicalTrials.gov ID
- NCT06566157
- Acronym / sponsor ID
- PROMOTE / 340693
- Conditions
- Wellbeing, Healthy, Mental Health
- Keywords
- Prebiotics, Gut microbiome, Microbiome, Metabolomics, Sequencing, Stress, Wellbeing
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Funding partners dissolved prior to study launch
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of SouthamptonUniversity, hospital or other
- Collaborators
- OptiBiotix Health Plc
- Study start
- 6 Jan 2025 (estimated)
- Primary completion
- 16 Sep 2025 (estimated)
- Study completion
- 16 Sep 2026 (estimated)
- First posted
- 22 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study will investigate whether taking a prebiotic for six weeks helps to reduce morning cortisol levels in healthy young adults with mild to moderate stress compared to a placebo. Individuals should continue with their usual lifestyle during the study. Other factors of wellbeing will also be assessed.
Detailed description
PROMOTE is a double blinded parallel randomised controlled-trial investigating if prebiotic supplementation reduce awakening salivary cortisol response, reported as area under the curve compared to a maltodextrin placebo in healthy young adults with a mild-to-moderate self reported stress score. There will be a focus on biological secondary outcomes to better understand how supplementation may influence the microbiome using metabolomics and sequencing techniques. In addition to other measures of wellbeing captured by questionnaires and activity monitors.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double blind, Placebo, Randomised
| Arm | Type | Receives |
|---|---|---|
| Prebiotic | Experimental | Dietary Supplement: PrebioticWellBiome® prebiotic complex Inulin 67%, Xylooligosaccharides (XOS) 27%, Magnesium Chloride (MgCl2) 9.8 % |
| Maltodextrin | Placebo comparator | Dietary Supplement: Maltodextrin (Corn)Maltodextrin (Corn origin) |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Aged 18-25 at time of recruitment
- Body Mass Index (18.5 - 29.9 kg) : Healthy - Overweight
- Stress score of 15≤ - ≥25 (DASS)
- Willing and with capacity to give informed consent to participate at time of recruitment
- Speak and comprehend English to a good standard
Key exclusion criteria (14 listed)
- Consuming ≥ 14 units of alcohol/week (6 x 175 mL of wine, 6 pints of 4% beer)
- Learning or behavioural difficulties (assessed on individual basis)
- Planning a pregnancy in the next 6 months, pregnant, lactating or had a recent birth ≥6 months
- Currently smoking or using e-cigarette, vape
- Vulnerable adults (with self reported sever or very severe stress score (DASS)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PrebioticAlso: WellBiome®, WellBiome® - Mineral Enriched Prebiotic Fibre Complex, Inulin, XOSWellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 % | Dietary supplement | Prebiotic |
| Maltodextrin (Corn)Also: Maltodextrin PlaceboPlacebo | Dietary supplement | Maltodextrin |
Primary outcome
Salivary Cortisol Awakening Response - Biological salivary cortisol (µg/dL)
Time frame: 6 collections across two working mornings per timepoint. (2 'baseline' - week 0 before supplementation; 2 'endpoint' - week 6 of supplementation ; 2 'follow-up' - within 3rd week (week 9) of supplement end)
Salivary Cortisol Awakening Response (µg/dL) Measured on awakening and hereafter at 0, 15 , 30, 45 minutes Quantified by ELISA and presented as area under the curve, for each timepoint. Example outcome: 'Awakening salivary cortisol response was significantly lower in the prebiotic group compared to the placebo mean difference: -2.27( 95CI-3.68, -0.87) group after 6 weeks of supplementation.' [result sourced from clinicaltrials.gov NCT0521254]
10 secondary outcomes
Good Sleeper Scale -15 items (GSS -15) self-reported sleep.
Time frame: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Depression Anxiety and Stress Scales 42-items (DASS-42) questionnaire. Wellbeing and subjective mental health assessment.
Time frame: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Faceal microbial sequencing and interventional group microbiota compositional change
Time frame: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).
Short Food Frequency Questionnaire (SFFQ): Diet quality score
Time frame: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Activity monitoring using activewear devices
Time frame: Continuous / 3 nights per 14 days (2 weeknights, 1 weekend night) depending on participants preference.
Urine Metabolomics (Untargeted)
Time frame: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).
Faeces Metabolomics (Untargeted)
Time frame: Participant home collection, 3 collections:24 hours before 'baseline visit' week 0, 24 hours before 'endpoint visit' week 6, 24 hours before follow-up visit (week 10).
Plasma Metabolomics (Untargeted)
Time frame: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Anthropometrics - Body composition
Time frame: 3 timepoints 'Baseline','Endpoint' and 'Follow-up' visits 0,6 and 10 weeks respectivley
Adverse effects monitoring
Time frame: Continuous monitoring from start to end of study for all participants
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- Background: PubMed 31525562Caspani G, Swann J. Small talk: microbial metabolites involved in the signaling from microbiota to brain. Curr Opin Pharmacol. 2019 Oct;48:99-106. doi: 10.1016/j.coph.2019.08.001. Epub 2019 Sep 14.
- Individual participant dataSharing planned: No. Individual participant data will be anonymised and submitted to open access repositories upon the consent and permission of the participants. Biological data will not be available for secondary analysis but raw exports of biological data in anonymous form can be made available on conditional request provided ethics approval from a suitable institution is met.
Related trials for Wellbeing
Recruiting
Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)
Mental Health and General Well-being
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Recruiting
Effects of Red Panax Ginseng Supplementation on Cognitive Performance and Emotional Well-Being in Young Healthy Adults
Mental Acuity
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jonathan R Swann, Professor principal investigator
University of Southampton, Faculty of Medicine - Human Development and Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prebiotic and Maltodextrin (Corn) in people with Wellbeing and Healthy, run by University of Southampton at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Salivary Cortisol Awakening Response - Biological salivary cortisol (µg/dL) (time frame: 6 collections across two working mornings per timepoint. (2 'baseline' - week 0 before supplementation; 2 'endpoint' - week 6 of supplementation ; 2 'follow-up' - within 3rd week (week 9) of supplement end)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06566157, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.